242 related articles for article (PubMed ID: 21733822)
1. Lung cancer chemoprevention with celecoxib in former smokers.
Mao JT; Roth MD; Fishbein MC; Aberle DR; Zhang ZF; Rao JY; Tashkin DP; Goodglick L; Holmes EC; Cameron RB; Dubinett SM; Elashoff R; Szabo E; Elashoff D
Cancer Prev Res (Phila); 2011 Jul; 4(7):984-93. PubMed ID: 21733822
[TBL] [Abstract][Full Text] [Related]
2. Celecoxib decreases Ki-67 proliferative index in active smokers.
Mao JT; Fishbein MC; Adams B; Roth MD; Goodglick L; Hong L; Burdick M; Strieter ER; Holmes C; Tashkin DP; Dubinett SM
Clin Cancer Res; 2006 Jan; 12(1):314-20. PubMed ID: 16397057
[TBL] [Abstract][Full Text] [Related]
3. Biological activity of celecoxib in the bronchial epithelium of current and former smokers.
Kim ES; Hong WK; Lee JJ; Mao L; Morice RC; Liu DD; Jimenez CA; Eapen GA; Lotan R; Tang X; Newman RA; Wistuba II; Kurie JM
Cancer Prev Res (Phila); 2010 Feb; 3(2):148-59. PubMed ID: 20103722
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
Elmets CA; Viner JL; Pentland AP; Cantrell W; Lin HY; Bailey H; Kang S; Linden KG; Heffernan M; Duvic M; Richmond E; Elewski BE; Umar A; Bell W; Gordon GB
J Natl Cancer Inst; 2010 Dec; 102(24):1835-44. PubMed ID: 21115882
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia.
Lam S; Mandrekar SJ; Gesthalter Y; Allen Ziegler KL; Seisler DK; Midthun DE; Mao JT; Aubry MC; McWilliams A; Sin DD; Shaipanich T; Liu G; Johnson E; Bild A; Lenburg ME; Ionescu DN; Mayo J; Yi JE; Tazelaar H; Harmsen WS; Smith J; Spira AE; Beane J; Limburg PJ; Szabo E;
Cancer Prev Res (Phila); 2016 Dec; 9(12):906-914. PubMed ID: 27658890
[TBL] [Abstract][Full Text] [Related]
6. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
7. Recruitment strategies for a lung cancer chemoprevention trial involving ex-smokers.
Kye SH; Tashkin DP; Roth MD; Adams B; Nie WX; Mao JT
Contemp Clin Trials; 2009 Sep; 30(5):464-72. PubMed ID: 19508900
[TBL] [Abstract][Full Text] [Related]
8. COX-2 inhibitor, celecoxib, may prevent lung cancer.
Oncology (Williston Park); 2011 Aug; 25(9):848-9. PubMed ID: 21936449
[No Abstract] [Full Text] [Related]
9. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway.
Duffield-Lillico AJ; Boyle JO; Zhou XK; Ghosh A; Butala GS; Subbaramaiah K; Newman RA; Morrow JD; Milne GL; Dannenberg AJ
Cancer Prev Res (Phila); 2009 Apr; 2(4):322-9. PubMed ID: 19336727
[TBL] [Abstract][Full Text] [Related]
10. Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer.
Vegeler RC; Yip-Schneider MT; Ralstin M; Wu H; Crooks PA; Neelakantan S; Nakshatri H; Sweeney CJ; Schmidt CM
J Surg Res; 2007 Nov; 143(1):169-76. PubMed ID: 17950089
[TBL] [Abstract][Full Text] [Related]
11. The dawn of a revolution in personalized lung cancer prevention.
Khuri FR
Cancer Prev Res (Phila); 2011 Jul; 4(7):949-53. PubMed ID: 21733817
[TBL] [Abstract][Full Text] [Related]
12. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.
Brandão RD; Veeck J; Van de Vijver KK; Lindsey P; de Vries B; van Elssen CH; Blok MJ; Keymeulen K; Ayoubi T; Smeets HJ; Tjan-Heijnen VC; Hupperets PS
Breast Cancer Res; 2013 Apr; 15(2):R29. PubMed ID: 23566419
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers.
Mao JT; Roth MD; Serio KJ; Baratelli F; Zhu L; Holmes EC; Strieter RM; Dubinett SM
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5835-41. PubMed ID: 14676104
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.
Sabichi AL; Lee JJ; Grossman HB; Liu S; Richmond E; Czerniak BA; De la Cerda J; Eagle C; Viner JL; Palmer JL; Lerner SP
Cancer Prev Res (Phila); 2011 Oct; 4(10):1580-9. PubMed ID: 21881030
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Lustberg MB; Povoski SP; Zhao W; Ziegler RM; Sugimoto Y; Ruppert AS; Lehman AM; Shiels DR; Mrozek E; Ramaswamy B; Layman RM; Brueggemeier RW; Shapiro CL
Clin Breast Cancer; 2011 Aug; 11(4):221-7. PubMed ID: 21729671
[TBL] [Abstract][Full Text] [Related]
16. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study.
Harris RE; Beebe-Donk J; Alshafie GA
Int J Biol Sci; 2007 Jun; 3(5):328-34. PubMed ID: 17589567
[TBL] [Abstract][Full Text] [Related]
17. Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung.
Szabo E
Cancer Prev Res (Phila); 2010 Feb; 3(2):128-31. PubMed ID: 20103726
[TBL] [Abstract][Full Text] [Related]
18. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Müller N; Schwarz MJ; Dehning S; Douhe A; Cerovecki A; Goldstein-Müller B; Spellmann I; Hetzel G; Maino K; Kleindienst N; Möller HJ; Arolt V; Riedel M
Mol Psychiatry; 2006 Jul; 11(7):680-4. PubMed ID: 16491133
[TBL] [Abstract][Full Text] [Related]
19. Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Papadimitrakopoulou VA; William WN; Dannenberg AJ; Lippman SM; Lee JJ; Ondrey FG; Peterson DE; Feng L; Atwell A; El-Naggar AK; Nathan CO; Helman JI; Du B; Yueh B; Boyle JO
Clin Cancer Res; 2008 Apr; 14(7):2095-101. PubMed ID: 18381950
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Ferrandina G; Ranelletti FO; Legge F; Lauriola L; Salutari V; Gessi M; Testa AC; Werner U; Navarra P; Tringali G; Battaglia A; Scambia G
Clin Cancer Res; 2003 Oct; 9(12):4324-31. PubMed ID: 14555502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
